These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 27288034)

  • 41. [Comparative results of the therapeutic action of morphazinamide and pyrazinamide combined with ethionamide in experimental tuberculosis in guinea pigs].
    Rözewska M
    G Ital Chemioter; 1967; 14(1):49-57. PubMed ID: 5622725
    [No Abstract]   [Full Text] [Related]  

  • 42. Multidrug-resistant tuberculosis without HIV infection: success with individualised therapy.
    Escudero E; Peña JM; Alvarez-Sala R; Vázquez JJ; Ortega A
    Int J Tuberc Lung Dis; 2006 Apr; 10(4):409-14. PubMed ID: 16602405
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment and follow-up of HIV-negative multidrug-resistant tuberculosis patients in an infectious diseases reference hospital, Buenos Aires, Argentina.
    Palmero DJ; Ambroggi M; Brea A; De Lucas M; Fulgenzi A; Martínez D; Mosca C; Musella R; Natiello M; Gonzalez C; Abbate E
    Int J Tuberc Lung Dis; 2004 Jun; 8(6):778-84. PubMed ID: 15182150
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Chemotherapy of leprosy. II. Sulfones and sulfonamides].
    Leiker DL
    Ned Tijdschr Geneeskd; 1980 Jan; 124(2):46-8. PubMed ID: 7374822
    [No Abstract]   [Full Text] [Related]  

  • 45. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon.
    Kuaban C; Noeske J; Rieder HL; Aït-Khaled N; Abena Foe JL; Trébucq A
    Int J Tuberc Lung Dis; 2015 May; 19(5):517-24. PubMed ID: 25868018
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical results obtained with Isoprodian in the treatment of new cases of pulmonary tuberculosis.
    Sighart H
    Scand J Respir Dis Suppl; 1978; 102():60-1. PubMed ID: 356259
    [No Abstract]   [Full Text] [Related]  

  • 47. Pharmacokinetics of prothionamide in patients with multidrug-resistant tuberculosis.
    Lee HW; Kim DW; Park JH; Kim SD; Lim MS; Phapale PB; Kim EH; Park SK; Yoon YR
    Int J Tuberc Lung Dis; 2009 Sep; 13(9):1161-6. PubMed ID: 19723408
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Doping in the peloton of antituberculosis drugs].
    Baulard AR
    Med Sci (Paris); 2005 Apr; 21(4):351-3. PubMed ID: 15811295
    [No Abstract]   [Full Text] [Related]  

  • 49. Surveillance of Mycobacterium tuberculosis susceptibility to second-line drugs in Hong Kong, 1995-2002, after the implementation of DOTS-plus.
    Kam KM; Yip CW
    Int J Tuberc Lung Dis; 2004 Jun; 8(6):760-6. PubMed ID: 15182147
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical predictors of aminoglycoside-induced ototoxicity in drug-resistant Tuberculosis patients on intensive therapy.
    Sogebi OA; Adefuye BO; Adebola SO; Oladeji SM; Adedeji TO
    Auris Nasus Larynx; 2017 Aug; 44(4):404-410. PubMed ID: 27832910
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence.
    Pontali E; Sotgiu G; D'Ambrosio L; Centis R; Migliori GB
    Eur Respir J; 2016 Feb; 47(2):394-402. PubMed ID: 26828052
    [No Abstract]   [Full Text] [Related]  

  • 52. [Comparison of the adverse effects of prothionamide and ethionamide in the treatment of pulmonary tuberculosis].
    Rózewska M
    Gruzlica; 1969 Dec; 37(12):1103-6. PubMed ID: 5368636
    [No Abstract]   [Full Text] [Related]  

  • 53. [Association of ethambutol-ethionamide or ethambutol-prothionamide in various forms of pulmonary tuberculosis].
    Meyer A; Nadjar-Fossé G
    Rev Tuberc Pneumol (Paris); 1969 Mar; 33(2):251-8. PubMed ID: 4247596
    [No Abstract]   [Full Text] [Related]  

  • 54. [Therapy of tuberculosis].
    Schaberg T; Lode H
    Dtsch Med Wochenschr; 1990 Nov; 115(47):1799-802. PubMed ID: 2226195
    [No Abstract]   [Full Text] [Related]  

  • 55. Isoniazid and rifampicin resistance mutations and their effect on second-line anti-tuberculosis treatment.
    Abate D; Tedla Y; Meressa D; Ameni G
    Int J Tuberc Lung Dis; 2014 Aug; 18(8):946-51. PubMed ID: 25199009
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Preventive chemotherapy in tuberculosis].
    Schönian U; Schmidt M; Ringelmann R
    Immun Infekt; 1986 Nov; 14(6):208-9. PubMed ID: 3804366
    [No Abstract]   [Full Text] [Related]  

  • 57. Failure of a prothionamide-containing oral antituberculosis regimen.
    Langton ME; Cowie RL
    S Afr Med J; 1985 Dec; 68(12):881. PubMed ID: 4071346
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Antituberculotics of the 2nd series in the surgery of pulmonary tuberculosis].
    Jancík E
    Z Tuberk Erkr Thoraxorg; 1965 Nov; 124(1):36-43. PubMed ID: 5899091
    [No Abstract]   [Full Text] [Related]  

  • 59. [The place of the thioamides in the treatment of pulmonary tuberculosis. (Role of TH 1321)].
    Molina C; Cheminat JC; Petit R
    Sem Hop; 1966 Jan; 42(2):99-105. PubMed ID: 4285613
    [No Abstract]   [Full Text] [Related]  

  • 60. [Advances in anti-tuberculosis therapy (author's transl)].
    Freeksen E; Rosenfeld M
    Prax Pneumol; 1976 Aug; 30(8):489-502. PubMed ID: 959157
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.